Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.

Leite, Carlos E; Mocelin, Clei A; Petersen, Guilherme O; Leal, Mirna B; Thiesen, Flavia V

Leite, Carlos E; Mocelin, Clei A; Petersen, Guilherme O; Leal, Mirna B; Thiesen, Flavia V.

Affiliation

Leite CE; Toxicology Institute, Pontifical Catholic University of Rio Grande do Sul, Av. Ipiranga 6681, Prédio 12, Bloco D, Sala 140, CEP: 90619-900, Porto Alegre - RS, Brazil.

Pharmacol Rep ; 61(2): 217-24, 2009.

Article in En | MEDLINE | ID: mdl-19443932

Subject(s)

Anti-Obesity Agents/pharmacology; Cannabinoid Receptor Modulators/antagonists & inhibitors; Endocannabinoids; Piperidines/pharmacology; Pyrazoles/pharmacology; Animals; Clinical Trials as Topic; Drug Approval; Humans; Piperidines/adverse effects; Piperidines/therapeutic use; Pyrazoles/adverse effects; Pyrazoles/therapeutic use; Receptor, Cannabinoid, CB1/drug effects; Receptor, Cannabinoid, CB1/physiology; Receptor, Cannabinoid, CB2/drug effects; Receptor, Cannabinoid, CB2/physiology; Rimonabant

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Piperidines / Pyrazoles / Anti-Obesity Agents / Endocannabinoids / Cannabinoid Receptor Modulators Type of study: Risk_factors_studies Limits: Animals / Humans Language: En Journal: Pharmacol Rep Journal subject: FARMACOLOGIA Year: 2009 Document type: Article Affiliation country: Brazil Country of publication: Switzerland

Search on Google

Add to My VHL

XML

PubMed Links